




Contents lists available at ScienceDirect

Sleep Health

Journal of the National Sleep Foundation

journal homepage: sleephealthjournal.org

The association between insomnia and prescription opioid use: results from a community sample in Northeast Florida



Mirsada Serdarevic, BA^{*}, Vicki Osborne, MSc, Catherine W. Striley, PhD MPE, Linda B. Cottler, PhD MPH

University of Florida, Department of Epidemiology, College of Public Health and Health Professions, College of Medicine, 2004 Mowry Road, PO Box 100231, Gainesville, FL, US 32610

ARTICLE INFO

Article history:

Received 13 February 2017

Received in revised form 5 July 2017

Accepted 14 July 2017

Keywords:

Prescription opioids

Insomnia

Community

Opioid use

ABSTRACT

Objective: The current analysis examines whether opioid use is associated with insomnia in a community sample, as the consequences of the growing epidemic of prescription opioid use continue to cause public health concern.

Study design: A cross-sectional study including 8433 members in a community outreach program, HealthStreet, in Northeast Florida.

Methods: Community Health Workers (CHWs) assessed health information, including use of opioids (i.e., Vicodin®, Oxycodone, Codeine, Demerol®, Morphine, Percocet®, Darvon®, Hydrocodone) from community members during field outreach. Insomnia was determined based on self-report: "Have you ever been told you had, or have you ever had a problem with insomnia?" Summary descriptive statistics were calculated and logistic regression modeling was used to calculate adjusted odds ratios (ORs) with 95% confidence intervals for insomnia, by opioid use status, after adjustment for demographics and other covariates.

Results: Among 8433 community members recruited (41% male; 61% Black), 2115 (25%) reported insomnia, and 4200 (50.3%) reported use of opioids. After adjusting for covariates, opioid users were significantly more likely to report insomnia than non-users (adjusted OR, 1.42; 95% CI, 1.25–1.61).

Conclusion: Insomnia was 42% more likely among those who reported using prescription opioids compared to those who did not. With one half of the sample reporting prescription opioid use, and a fourth reporting insomnia, it is important to further investigate the relationship between the two. Findings provide useful preliminary information from which to conduct further analyses.

© 2017 National Sleep Foundation. Published by Elsevier Inc. All rights reserved.

Introduction

Insomnia is one of the most common sleep disorders with approximately 30% of the general population reporting brief symptoms of insomnia and 10% reporting chronic insomnia.^{1,2}

The International Classification of Sleep Disorders, 3rd edition (ICSD-3) defines insomnia as "a repeated difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity and circumstances for sleep, and results in some form of daytime impairment."³ Insomnia usually occurs independently or in combination with psychiatric and medical disorders, such as depression,⁴ anxiety,⁵ pain,⁶ and sleep-disordered breathing (SDB). Half of all individuals suffering from SDB (50%) also report insomnia.⁷ In addition to difficulty initiating or maintaining sleep, the diagnostic criteria for primary insomnia from the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)* also includes that the difficulty causes distress or impairment in social, occupational,

or other areas of functioning that does not occur exclusively during another sleep disorder, and that it is not due directly to physiological effects of a substance or medical condition.⁸ Insomnia can cause psychological,⁹ occupational,^{10,11} and economical¹² consequences. For example, the National Transportation Safety Board (NTSB) has estimated that 57% of crashes leading to truck driver fatality were caused by fatigue,¹³ which may have been precipitated by inability to sleep due to insomnia or work requirements, and workers who report insomnia are much more likely to report injuries or industrial accidents than workers who report sleeping well.¹⁴

Prescription opioid use has increased dramatically in the United States in the last 25 years.^{16,15} The number of opioid prescriptions almost tripled from 76 million to 207 million between 1991 and 2013, with the United States being one of the largest consumers globally.¹⁵ The increase in opioid prescriptions is problematic because of the associated consequences related to prescription opioid misuse and related to an increase in associated health problems. According to the Centers for Disease Control and Prevention (CDC), nearly 91 Americans die daily due to overdose of prescription opioids.¹⁶ This epidemic does not just have a direct effect on those who use opioids,

^{*} Corresponding author. Tel.: +1 352 294 5953; fax: +1 352 273 5365.
E-mail address: mserdarevic@ufl.edu (M. Serdarevic).

but its consequences have far reaching effects on both families and whole communities all over the nation.

Previous studies have investigated the relationship between some substances and disrupted sleep, including the association between sleep and cigarette smoking,¹⁷ anti-hypertensive drugs,¹⁸ alcohol,¹⁹ benzodiazepines,²⁰ hypnotics and anxiolytics.²¹ Common side effects from prescription opioid use are sleep disturbances such as SDB²² and reduction in sleep efficiency.²³ Specifically, a clear relationship between SDB and opioid use has been established²⁴ with studies reporting prevalence of SDB ranging from 42% to 85% among individuals taking chronic opioids.²⁵ Insomnia has been found to be common among individuals with opioid use disorder who are going through withdrawal.⁸ Recently, Dolsen and Harvey reported that insomnia was related to heroin use among individuals seeking substance use treatment.²⁶ Additionally, another study by Tran et al., found opioid use to be associated with five times the odds of developing or at risk of developing a sleep disorder.²⁷ Insomnia may be an unintended pharmacological effect (side effect) of opioids. While such a relationship is likely, there is limited, but suggestive, information on the association between prescription opioid use and insomnia. This paper presents an analysis of prescription opioid use and insomnia, which was conducted among a large sample of community members in Northeast Florida. We hypothesize that insomnia will be more prevalent among individuals who report using prescription opioids in their lifetime compared to those who do not report prescription opioid use.

Methods

Setting and subjects

Participants were part of a community outreach program, HealthStreet, based in Gainesville, Florida. Through HealthStreet, Community Health Workers (CHWs) directly engage community members to reduce health disparities in health research participation.²⁸ CHWs are trained and certified to make connections with people where they live and work to assess their health conditions and concerns with a University of Florida Institutional Review Board (IRB) approved Health Intake. Upon obtaining signed informed consent, the CHWs assess health information such as demographics and social determinants of health, research perceptions, medical conditions, and drug use. These data are then used to link people to social and medical services and opportunities to participate in health research. We were interested in examining the history of insomnia and prescription opioid use. These are the focus of these analyses among 8433 community members who were interviewed between November 2011 and January 2017.

Measures

As part of an ongoing study this secondary data analysis used sociodemographic variables including age, gender, race (Black/African-American, White, or Other), ethnicity (Hispanic or Latino), marital status (never married; currently married; or separated, divorced, or widowed), and employment (yes or no). Additional self-reported variables were history of depression, history of anxiety, history of pain (back pain, headaches, or arthritis), and history of cancer elicited as: “Have you ever been told you had, or have you ever had a problem with [medical condition]?” Self-reported insomnia was also assessed by asking: “Have you ever been told you had, or have you ever had a problem with insomnia?”

Additional self-report measures for substance use included cigarette use, at risk alcohol use, and prescription opioid use. Cigarette use was assessed for lifetime use: “Have you ever smoked cigarettes?” At risk alcohol use was assessed for past 30 day use: “Within the last

30 days, have you had more than (4 for men, 3 for women) drinks like beer, wine, liquor in a single day?” We do not know if members only drank this quantity of alcohol once in the past 30 days or multiple times; however, we have used this question as a proxy for at risk drinking. Past 30 day and lifetime use of opioids was assessed: “Have you ever used prescription pain medication like Vicodin®, Oxycodone, codeine, Demerol®, morphine, Percocet®, Darvon®? If yes, have you used prescription pain medications in the last 30 days?” Responses for the insomnia, opioid use, depression, anxiety, and alcohol use variables were coded as yes/no. Persons were coded as a never user, a lifetime but not past 30 day user or a past 30 day user. We used the term prescription opioids to distinguish between these and illicit opioids e.g., heroin; however, it should be noted that we cannot confirm whether members had legitimate prescriptions for these opioids. Community members could have been using these opioids medically or non-medically.

Data analysis

Data analysis was conducted using SAS, version 9.4.²⁹ Demographic data were summarized using descriptive statistics. A chi-square test of independence was performed to compare whether there was a significant association between all variables and insomnia. An independent t-test was conducted to compare mean age in individuals who reported insomnia and those who did not. Multivariate logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals for insomnia. The covariates of age, gender, ethnicity, race, marital status, employment, history of depression, history of anxiety, history of cancer, cigarette use, alcohol use, and history of pain along with prescription opioid use were included in the model. The Hosmer-Lemeshow test was used to confirm adequate model fit.

Results

As shown in Figs. 1, 11,218 community members received a 3 minute contact with a CHW and 8611 stopped to talk and were assessed with the Health Intake questionnaire. After exclusion of persons under 18 and over 90, the sample size was reduced to 8462 then further reduced to 8433 to account for 29 people who did not provide information on insomnia. The sample was 58.8% female, 60.8% Black, 21.1% are married, 35.1% employed, 27.9% with depression, 23.0% with anxiety, 51.9% used cigarettes in their lifetime, 23.9% alcohol users in the past 30 days, and 65.7% with pain. In addition, 3475 (41.3%) reported neither insomnia nor prescription opioid use, 707 (8.4%) reported insomnia without any prescription opioid use, 2831 (33.6%) reported prescription opioid use without insomnia, and 1405 (16.7%) reported both insomnia and prescription opioid use.

Table 1 displays the demographic characteristics of participants, stratified by reported insomnia, and results of the crude tests of association. Overall, the mean age of participants was 44.2 years and those who reported insomnia were significantly older than those who did not (47.1 years vs 43.3 years). Those who reported insomnia compared to those who did not were significantly more likely to be female, Caucasian, not employed, report depression, anxiety, pain, cancer, cigarette use, and lifetime and past 30 day only opioid use ($P < .0001$).

After adjustment for age, gender, ethnicity, race, marital status, employment, history of depression, history of anxiety, history of pain, lifetime use of cigarettes and at risk alcohol use in the past 30 days, opioid users were significantly more likely to report insomnia than non-users. There was no evidence of effect modification after stratification by sex (data not shown). Table 2 provides results of the adjusted multivariate logistic regression model predicting self-

Download English Version:

<https://daneshyari.com/en/article/5039493>

Download Persian Version:

<https://daneshyari.com/article/5039493>

[Daneshyari.com](https://daneshyari.com)